Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in Mexico: special focus on Acinetobacter baumannii
- PMID: 20693798
- DOI: 10.1159/000319903
Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in Mexico: special focus on Acinetobacter baumannii
Abstract
Our aim was to determine the prevalence of multidrug resistance of Acinetobacter baumannii and other pathogens at a tertiary-care teaching hospital in Mexico over a 3-year period. Clinical isolates of A. baumannii (n = 550), Pseudomonas aeruginosa (n = 250), some Enterobacteriaceae species (n = 500) and Staphylococcus aureus (n = 250) collected over a 3-year period were included. Susceptibility tests were performed by the broth microdilution method. 74% of A. baumannii, 40% of Escherichia coli, 34% of P. aeruginosa, 22% of Klebsiella pneumoniae, 9% of Enterobacter cloacae, and 7% of Serratia sp. were multidrug resistant. 59% of A. baumannii clinical isolates were meropenem-resistant. A. baumannii isolates from the lower respiratory tract were the most susceptible, followed by urine clinical isolates. Species from Enterobacteriaceae showed susceptibility rates higher than 90% to meropenem and tigecycline and Serratia sp. showed the highest susceptibility to the drugs evaluated. For P. aeruginosa, the most potent drug was levofloxacin, followed by meropenem and piperacillin-tazobactam. With regard to S. aureus, 96% of the isolates were susceptible to vancomycin, followed by tigecycline and minocycline (91% of strains susceptible). The high multidrug resistance observed underscores the need for surveillance of bacterial drug resistance.
Copyright © 2010 S. Karger AG, Basel.
Similar articles
-
Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.Diagn Microbiol Infect Dis. 2011 Mar;69(3):335-41. doi: 10.1016/j.diagmicrobio.2010.10.030. Diagn Microbiol Infect Dis. 2011. PMID: 21353962
-
In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.Int J Antimicrob Agents. 2006 Mar;27(3):224-8. doi: 10.1016/j.ijantimicag.2005.10.012. Epub 2006 Feb 7. Int J Antimicrob Agents. 2006. PMID: 16464562
-
[Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics].Mikrobiyol Bul. 2008 Apr;42(2):321-9. Mikrobiyol Bul. 2008. PMID: 18697430 Turkish.
-
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Expert Rev Anti Infect Ther. 2010 Jan;8(1):71-93. doi: 10.1586/eri.09.108. Expert Rev Anti Infect Ther. 2010. PMID: 20014903 Review.
-
Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology.Int J Antimicrob Agents. 2015 Jun;45(6):568-85. doi: 10.1016/j.ijantimicag.2015.03.001. Epub 2015 Mar 24. Int J Antimicrob Agents. 2015. PMID: 25857949 Review.
Cited by
-
Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PLoS One. 2024 Dec 16;19(12):e0311124. doi: 10.1371/journal.pone.0311124. eCollection 2024. PLoS One. 2024. PMID: 39680587 Free PMC article.
-
genetic determinants of intrinsic colistin tolerance in Acinetobacter baumannii.Infect Immun. 2013 Feb;81(2):542-51. doi: 10.1128/IAI.00704-12. Epub 2012 Dec 10. Infect Immun. 2013. PMID: 23230287 Free PMC article.
-
Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review.Eur J Clin Microbiol Infect Dis. 2022 Jul;41(7):1003-1022. doi: 10.1007/s10096-020-04121-1. Epub 2021 Jan 5. Eur J Clin Microbiol Infect Dis. 2022. PMID: 33403565 Free PMC article. Review.
-
Loss of mitochondrial protein Fus1 augments host resistance to Acinetobacter baumannii infection.Infect Immun. 2013 Dec;81(12):4461-9. doi: 10.1128/IAI.00771-13. Epub 2013 Sep 16. Infect Immun. 2013. PMID: 24042119 Free PMC article.
-
Discovery of a Monoclonal Antibody That Targets Cell-Surface Pseudaminic Acid of Acinetobacter baumannii with Direct Bactericidal Effect.ACS Cent Sci. 2024 Feb 7;10(2):439-446. doi: 10.1021/acscentsci.3c01507. eCollection 2024 Feb 28. ACS Cent Sci. 2024. PMID: 38435534 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical